Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Schwab US Large Cap Growth ETF trades at $34.58. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SCHG | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $35.30 |
52-Week Low | $278.09 | $28.10 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SCHG trades at $34.65 with a 0.32% daily gain, showing bullish technical momentum with strong moving average support. The ETF's concentrated exposure to AI-driven tech leaders like Nvidia, Apple, and Microsoft positions it for growth amid projected multi-trillion dollar AI infrastructure spending. Recent institutional buying and positive analyst coverage highlight confidence in its large-cap growth strategy despite elevated valuations around 32x P/E.
The outlook remains positive given SCHG's strategic positioning in AI growth themes, though concentration risk in top holdings and sensitivity to interest rate changes present challenges. Current technical strength suggests near-term upside potential to resistance at $35, while long-term performance depends on sustained tech sector leadership and AI adoption trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
